You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors

Article metrics

Article menu

Download PDFPDF

Oral Abstracts
Opening Ceremony and Plenary 1: Oral Abstract Presentations
O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to April 2024

AbstractFullPdf
Nov 2021139054
Dec 202189042
Jan 202284038
Feb 20224009
Mar 202263016
Apr 202249013
May 202249019
Jun 202286028
Jul 202261010
Aug 202259015
Sep 202286016
Oct 202272018
Nov 202295017
Dec 20223707
Jan 20236907
Feb 202327012
Mar 20234206
Apr 20232804
May 20232904
Jun 20235206
Jul 20232605
Aug 2023100022
Sep 20231307
Oct 20232105
Nov 20235609
Dec 20235107
Jan 20241406
Feb 20242608
Mar 20242108
Apr 20242602
Total16100420